Amylyx Pharmaceuticals, INC Form 4 insider transactions

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold shares of common stock on September 30, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Joshua B. Cohen, Co-CEO of Amylyx Pharmaceuticals, exercised stock options and acquired 1,857 shares of common stock at a price of $1.57 on September 23, 2024.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, exercised stock options and acquired 34,449 shares of common stock on September 12, 2024.

Chief Financial Officer of Amylyx Pharmaceuticals, James M. Frates, recently purchased 40,000 shares of the company's common stock at an average price of $2.5342.

Director Karen Firestone increased her stake in Amylyx Pharmaceuticals by purchasing 50,000 shares of common stock at an average price of $2.1318 on September 5, 2024.

James M. Frates, CFO of Amylyx Pharmaceuticals, files an amended Form 4 to correct an overstatement of beneficially owned securities.

Director George M. Milne Jr. of Amylyx Pharmaceuticals, Inc. [AMLX] acquired 100,000 shares of common stock at an average price of $2.198 on September 3, 2024, increasing his total holdings to 858,571 shares.

Paul R. Fonteyne, a director at Amylyx Pharmaceuticals, acquired stock options for 25,000 shares on June 6, 2024.

Karen Firestone, a director at Amylyx Pharmaceuticals, reported the acquisition of a stock option to purchase 25,000 shares of common stock.

Bernhardt G. Zeiher, a director of Amylyx Pharmaceuticals, acquired stock options exercisable for 5,753 shares of common stock on June 6, 2024.

George M. Milne Jr., a director at Amylyx Pharmaceuticals, acquired 25,000 stock options on June 6, 2024.

Daphne Quimi, a director at Amylyx Pharmaceuticals, acquired stock options for 25,000 shares on June 6, 2024.

Director Daphne Quimi recently acquired additional shares of Amylyx Pharmaceuticals, signaling confidence in the company's future.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 10,455 shares of common stock at an average price of $1.8799 per share under a pre-arranged trading plan.

Chief Financial Officer James M. Frates of Amylyx Pharmaceuticals received stock options and restricted stock units, as detailed in a recent SEC filing.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, acquired stock options and restricted stock units (RSUs) as part of her compensation.

Co-CEO Justin B. Klee reports acquiring shares and stock options in Amylyx Pharmaceuticals, signaling potential confidence in the company's future.

Chief Medical Officer Camille L. Bedrosian reports acquisition of common stock and stock options in Amylyx Pharmaceuticals.

Bernhardt G. Zeiher, a director of Amylyx Pharmaceuticals, acquired 50,000 stock options on March 14, 2024, according to a recent SEC filing.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold 4,135 shares of common stock on March 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Chief Financial Officer of Amylyx Pharmaceuticals, James M. Frates, reports the sale of shares to cover tax obligations related to vesting restricted stock units and a transfer of shares to a trust.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 1,540 shares of common stock on March 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Chief Financial Officer of Amylyx Pharmaceuticals, James M. Frates, reports acquisition of 40,000 shares of common stock and 60,000 stock options.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, reports the acquisition of restricted stock units and stock options.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, receives restricted stock units and stock options.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 2,838 shares of common stock on February 23, 2024, to cover tax withholding obligations related to vesting restricted stock units.